Affibody Ab

Amylonix Ab

Stefan Ståhl

John Löfblom

Elin Gunneriusson

Fredrik Nilsson

Tove Eriksson

Fredrik Frejd

Andreas Jonsson

Torleif Härd

Mikaela Friedman

Jörgen Carlsson

Hanna Lindberg

Nina Kronqvist

Magdalena Malm

The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid &#x3b2; (A&#x3b2;) peptides (in the following referred to as A&#x3b2;), comprising the amino acid sequence EXXYXXNLXA XQLCAXIXXXED (SEQ ID NO:632). The present disclosure also relates to the use of such A&#x3b2; peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.

Alzheimer A&#x3b2; peptide binding polypeptide

The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EXXXA XXEIW XLPNL XXXQXXAFIXXLXD, and ii) an amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.

HER3 binding polypeptides

The present disclosure relates to polypeptides which bind to human epidermal growth factor receptor 3 (HER3) and to use of such polypeptides in imaging and therapy. The disclosure provides an HER3 binding polypeptide comprising a HER3 binding motif, which motif consists of the amino acid sequence EKYXAYXEIW XLPNLTXXQXAAFIGXLXD (SEQ ID NO:110).

This invention relates to polypeptides which bind to EGFR family receptors and to applications of those polypeptides in medicine, veterinary medicine, diagnosis diagnostics and imaging.

Polypeptides

A polypeptide is provided, which has a binding affinity for HER2 and which is related to a domain of staphylococcal protein A (SPA) in that the sequence of the polypeptide corresponds to the sequence of the SPA domain having from 1 to about 20 substitution mutations. Nucleic acid encoding the polypeptide, as well as expression vector and host cell for expressing the nucleic acid, are also provided. Also provided is the use of such a polypeptide as a medicament, and as a targeting agent for directing substances conjugated thereto to cells overexpressing HER2. Methods, and kits for performing the methods, are also provided, which methods and kits rely on the binding of the polypeptide to HER2.

Growing community of inventors

Stockholm, Sweden

Stefan Ståhl